Want to see AU:BGT full AI Analyst Report?
Bio-Gene Technology Ltd. (BGT) AI Stock Analysis
Bio-Gene Technology Ltd.
(ASX:BGT)
The score is driven primarily by very weak financial performance, including no revenue, recurring losses, and continued cash burn. Technical indicators are mixed but remain unfavorable overall, while the negative P/E and absence of dividend income provide no valuation support.
Bio-Gene Technology Ltd. (BGT) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 3.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 317.26K
- Price to Earnings (P/E)
- -1.7
- Beta (1Y)
- 0.26
- Revenue Growth
- ―
- EPS Growth
- 38.52%
- Country
- Australia
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Agricultural Inputs
Bio-Gene Technology Ltd. Business Overview & Revenue Model
Company Description
Bio-Gene Technology Limited, an agricultural technology firm based in Australia, focuses on the development and commercialization of insecticides and pesticides. These solutions are designed for a range of uses, encompassing animal health, crop prote...
Bio-Gene Technology Ltd. Financial Statement Overview
Summary
Very weak financial performance: revenue has fallen to zero, losses remain substantial, operating cash flow is generally negative, and shareholder equity has been eroded. Minimal debt and modest recent improvement provide limited support.
Income Statement
18Very NegativeBalance Sheet
35NegativeCash Flow
25Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 18.32K | 149.23K | 445.73K |
| Gross Profit | -42.00K | -42.00K | -245.78K | -301.45K | -164.04K | 178.59K |
| EBITDA | -3.37M | -3.36M | -2.58M | -2.97M | -3.14M | -2.92M |
| Net Income | -2.33M | -2.33M | -2.58M | -2.41M | -3.10M | -2.91M |
Balance Sheet | ||||||
| Total Assets | 2.61M | 2.61M | 2.15M | 3.16M | 3.84M | 7.30M |
| Cash, Cash Equivalents and Short-Term Investments | 1.94M | 1.94M | 1.14M | 2.21M | 2.99M | 6.34M |
| Total Debt | 0 | 0 | 51.21K | 0 | 0 | 0 |
| Total Liabilities | 519.76K | 519.76K | 522.98K | 368.45K | 613.88K | 1.03M |
| Stockholders Equity | 2.09M | 2.09M | 1.63M | 2.79M | 3.22M | 6.27M |
Cash Flow | ||||||
| Free Cash Flow | -1.94M | 0 | -2.54M | -2.76M | -3.28M | 36.67K |
| Operating Cash Flow | -1.94M | -1.94M | -2.54M | -2.75M | -3.28M | 43.52K |
| Investing Cash Flow | 0 | 0 | 0 | -5,698 | 0 | -6,840 |
| Financing Cash Flow | 2.74M | 2.74M | 1.47M | 1.98M | -75.00K | 4.41M |
Bio-Gene Technology Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BGT, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 37.15 is Neutral, neither overbought nor oversold. The STOCH value of -51.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BGT.
Bio-Gene Technology Ltd. Peers Comparison
Overall Rating
AU:BIT43Neutral
AU:TRP43Neutral
AU:VBS42Neutral
AU:BOT41Neutral- AU:BGT39Underperform
AU:CMB37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:BIT | 43Neutral | AUD 5.57M | -5.34 | -54.03% | ― | ― | -100.00% |
| AU:TRP | 43Neutral | AUD 5.06M | -1.35 | -52.04% | ― | 32.22% | -26.53% |
| AU:VBS | 42Neutral | AUD 4.66M | 2.60 | 206.11% | ― | ― | ― |
| AU:BOT | 41Neutral | AUD 27.63M | -0.31 | -118.74% | ― | 499.47% | 31.20% |
| AU:BGT | 39Underperform | AUD 5.69M | -1.73 | -143.11% | ― | ― | 38.52% |
| AU:CMB | 37Underperform | AUD 11.77M | -1.43 | -247.44% | ― | -4.24% | 33.39% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:BGT | Bio-Gene Technology Ltd. | 0.01 | -0.01 | -48.00% | |
| AU:BIT | Biotron Limited | ― | ― | ― | |
| AU:VBS | Vectus Biosystems Limited | 0.07 | -0.12 | -60.53% | |
| AU:TRP | Tissue Repair Ltd | 0.12 | -0.20 | -62.90% | |
| AU:CMB | Regeneus Ltd. | 0.36 | -0.14 | -28.00% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.12 | -92.00% |
Bio-Gene Technology Ltd. Corporate Events
Bio-Gene plans issue of 6.5 million long-dated options
Bio-Gene Technology Ltd. has lodged a new Appendix 3B with the ASX outlining a proposed issue of securities via a placement or other type of capital raising. The company plans to issue up to 6.5 million options in a new class, exercisable at $0.035 a...
Bio-Gene Secures $343,000 R&D Tax Incentive to Advance Bio‑Insecticide Pipeline
Bio-Gene Technology Limited, an Australian developer of nature‑derived bio‑insecticides, is advancing products such as Flavocide and Qcide to combat insecticide resistance with reduced impact on human health and the environment. Its techn...
Bio-Gene sets 2026 AGM date and director nomination deadline
Bio-Gene Technology Limited has scheduled its 2026 Annual General Meeting for Monday, 30 November 2026, and set Monday, 19 October 2026 as the deadline for shareholders or other eligible parties to submit written nominations for director positions. T...
Bio-Gene Details ASX Governance Compliance, Delays Gender Targets
Bio-Gene Technology Limited has outlined its adherence to the ASX Corporate Governance Council’s fourth-edition principles, confirming broad compliance with recommendations on board charters, director appointments, written executive agreements...
Bio-Gene lodges updated ASX corporate governance statement and Appendix 4G
Bio-Gene Technology Limited has lodged its updated corporate governance statement and accompanying Appendix 4G with the ASX for the financial year ended 30 June 2026, confirming compliance with key disclosure obligations under Listing Rules 4.7.3, 4....
Bio-Gene Posts Narrower 2026 Loss, Holds Asset Backing Steady
Bio-Gene Technology Limited has released its final report and 2026 annual report for the year ended 30 June 2026, detailing its financial and operational performance for shareholders. The company reported no revenue from ordinary activities and a red...
Bio-Gene Technology Issues 69 Million Unquoted Options
Bio-Gene Technology Ltd has notified the market of the issue of a large tranche of unquoted equity securities in the form of options. The company will issue 69,221,150 options, expiring on October 15, 2027, with an exercise price of A$0.035, which ar...
Bio-Gene Director Boosts Indirect Stake Through Share Placement and Options
Bio-Gene Technology Limited has reported a change in director Timothy Grogan’s indirect interests in the company’s securities via Grogan Pty Ltd, reflecting a substantial increase in his share and option holdings. Following a recent trans...
Bio-Gene Raises A$3.3m Through Completed Share Placement and Option Issue
Bio-Gene Technology Limited has completed the second tranche of a share placement and associated share purchase plan underwriting, issuing 51,980,000 fully paid shares following shareholder approval at its recent extraordinary general meeting. The ca...
Bio-Gene Technology Seeks ASX Quotation for 15.2 Million New Shares
Bio-Gene Technology Ltd., an ASX-listed biotechnology company trading under the code BGT, develops and commercialises biological technologies with a focus on innovative solutions for the life sciences and related markets.The company has applied for q...
Bio-Gene Seeks ASX Quotation for 34.8 Million New Shares
Bio-Gene Technology Ltd., an ASX-listed biotechnology firm, has moved to expand its listed equity base with a new batch of ordinary fully paid shares. The company’s securities, identified under the BGT ticker, continue to form the foundation of...
Bio-Gene Technology Seeks Quotation for 2 Million New ASX Shares
Bio-Gene Technology has lodged a new application with the ASX for quotation of additional ordinary fully paid shares. The company is seeking quotation for 2,000,000 BGT securities, reflecting a modest expansion of its listed equity base.The new secur...
Bio-Gene Wins Shareholder Backing for Capital Plans at Extraordinary Meeting
Bio-Gene Technology Limited is an Australian agritech company developing novel bio-insecticides to address insecticide resistance and the demand for natural pest control solutions. Its products, including proprietary brands Flavocide and Qcide, are b...
Bio-Gene advances Asian vector control push and Japan launch plans for Qcide
Bio-Gene has expanded evaluation of its Flavocide and Qcide mosquito control technologies into Asia, with WHO-aligned testing in Singapore and the wider region targeting key disease-carrying species such as Aedes aegypti and Aedes albopictus. The pro...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026